Adeira Pharma

Adeira Pharma is a private, preclinical biotech leveraging a versatile targeted nanoparticle platform to overcome historical drug formulation challenges. Its core technology enables the encapsulation or surface attachment of diverse therapeutic payloads, aiming to enhance pharmacokinetics, reduce toxicity, and improve targeted delivery. The company is currently seeking development partners for its lead reformulation candidates, primarily in oncology, and operates a partnership-focused business model without disclosed revenue.

Proprietary targeted lipid nanoparticle (LNP) formulation platform for encapsulating or attaching small molecules, proteins, peptides, and nucleic acids. Features a lipid core and surfactant monolayer, allows antibody/peptide targeting, and demonstrates high stability and improved pharmacokinetics in preclinical models.

Adeira competes in the crowded drug delivery and nanoparticle formulation space, facing competition from large pharmaceutical companies with internal capabilities (e.g., for liposomal doxorubicin, Abraxane) and numerous biotech startups. Its differentiation hinges on demonstrating superior targeting, stability, and payload versatility compared to existing LNP and other nano-formulation technologies.